ADMA Biologics (NASDAQ: ADMA) reported Q3 EPS of $0.15, $0.02 better than the analyst estimate of $0.13. Revenue for the quarter came in at $119.8 million versus the consensus estimate of $105.96 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.